With one manufacturer and little money to be made, supplies of a critical cancer drug are dwindling
HYACINTH EMPINADO/STAT
Companies have little incentive to make a drug like BCG, which is remarkably effective at treating bladder cancer but hardly lucrative.
No hay comentarios:
Publicar un comentario